Tazemetostat and Palbociclib With CPX-351for R/R AML

Clinical trial NCT05627232 · RECRUITING

Trial details

NCT number: NCT05627232
Sponsor: Thomas Jefferson University
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2023-08-28
Primary completion: 2028-01-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.